Starget Pharma develops Smart Targeted Radioligands (STRs) for precision oncology of hard-to-heal cancers. Their AI-driven peptide-based discovery engine rapidly identifies radioligands that deliver high-energy radiation precisely to tumoral and metastatic cancer cells while sparing healthy tissues. This technology aims to accelerate the discovery and development of novel, targeted peptide radioligands for a broad range of cancers, offering new hope to patients.